The iRGD conjugation can improve tumor targeting and tissue penetration by more than four-fold, resulting in enhanced suppression of tumor cell proliferation in vitro and in vivo.141 More recently, Erel-Akbaba et al. constructed iRGD-conjugated solid lipid nanoparticles loaded with EGFR and PD-L1 siRNAs against glioblastoma. The gene discussed is CD274; the disease is neoplasm.